Business Wire

Certa Raises Oversubscribed $35M Series B to Further Reduce Third-Party Management Friction

7.9.2023 16:00:00 EEST | Business Wire | Press release

Share

The all-in-one third-party management platform, Certa, today announced it has raised a 2x oversubscribed Series B led by Fin Capital, and Vertex Ventures Southeast Asia and India, with participation from Tru Arrow Partners. Existing investors Point72 Ventures, BDMI, which is part of Bertelsmann's corporate venture arm Bertelsmann Investments, the family office of Bernard Arnault’s Aglae Ventures, The Chainsmokers-backed Mantis VC, and GOAT Capital also participated in the round. This raise brings the total institutional investment in Certa to $50M to date.

Today’s organizations are increasingly global interconnected ecosystems of thousands of suppliers, partners, and clients. Each relationship adds risks like data security, privacy, and fraud. Additionally, companies deal with ever-increasing compliance burdens, such as the recent Uyghur Forced Labor Prevention Act (UFLPA) in the U.S. and the German Supply Chain Due Diligence Act (LkSG), along with pressing Environmental, Social, and Governance (ESG) goals. A firm's competitive edge depends on its ability to work with third parties efficiently, safely, and swiftly. Existing systems at best offer point solutions which are often a pain to integrate, struggle to manage interconnected risks, and third-party data ends up siloed across multiple systems. Certa provides the most comprehensive and intelligent platform for global third-party management across procurement, compliance, ESG, and legal.

The results achieved by Certa’s clients speak volumes. “Business impact has been tremendous; we’ve been able to reduce our cycle times by over 78 percent,” said Linda Chuan, VP & Chief Procurement Officer at Box.

“We’ve been able to reduce our operating costs by 50 percent year over year and increase our on-time payments from around 40 to 95 percent,” echoed Mark Arrigotti, Head of Finance Operations at Uber.

To date, Certa has helped clients onboard and monitor millions of companies across 120 countries supporting 41 languages.

“This investment in a tough economic environment underscores the demand for a more complete, modern solution to manage third-party relationships,” said Jag Lamba, founder and CEO of Certa. “It is a testament to Certa’s best in class technology and the value we have delivered to clients, many of whom are large Fortune 500 companies. We are energized by the faith put in us by our rockstar investors and believe Certa is poised to be a next-gen category leader in third-party management.”

Certa will use the funding to bolster its go-to-market engine, expand its reach into new high-growth markets like Europe, and accelerate adoption. Since customer feedback is in the company’s DNA, Certa is pioneering the use of advanced Generative AI to streamline third-party ecosystems.

“Managing third parties is more than just risk and compliance - customers are looking for a full stack solution,” said Logan Allin, Managing Partner and Founder of Fin Capital and the newest Certa Board Member. “With its ability to redefine how businesses work and grow together, it’s an honor to partner with Certa on their journey as both an investor and board member.”

For more information, visit www.getcerta.com. Follow Certa on Twitter and Linkedin to stay up to date.

About Certa

Certa helps Fortune 500 firms with global third-party compliance, risk management, and ESG. Certa is a comprehensive platform to manage all third parties globally which can be personalized via a no-code studio and an open architecture with 120+ ready-made integrations.

Certa has been recognized as a Top 50 Procurement Providers to Watch in 2022 by Spend Matters, and a Representative Vendor in Gartner’s 2022 Market Guide for Third Party Risk Management Solutions and IT Vendor Risk Management Solutions.

For more information or to schedule a demo, visit our website, Twitter, and Linkedin.

About Fin Capital

Fin Capital is a global asset manager focused on full life cycle investing in B2B FinTech companies. The firm seeks to add meaningful value beyond capital throughout the partnership lifecycle with its proprietary platform, Lighthouse, hands-on operating playbooks, and deep operational experience. Fin is headquartered in San Francisco with offices in Los Angeles, London, Miami, and New York.

About Vertex Ventures Southeast Asia and India (VVSEAI)

Vertex Ventures Southeast Asia and India partners with founders who are creating innovative, transformative and scalable businesses. It has a long and strong track record of investing in early-stage startups and building champions like Grab, PatSnap, Nium, FirstCry, XPressBees, Licious, 17LIVE, and others. VVSEAI supports its portfolio companies with unmatched operating experience and deep access to the capital, talent, partners and customers they need to build truly global businesses. VVSEAI is one of six major funds in the Vertex Global Network which includes Vertex Ventures Israel, Vertex Ventures China, Vertex Ventures US, Vertex Ventures HC and Vertex Growth. These funds each focus on investments in their region and industry specialization. With the combined regional expertise and global reach, each team can leverage the Vertex Platform to get a broad view of innovation and share learning experiences across the world.

For more information, please visit: https://www.vertexventures.sg/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lizzy Harris for Certa
lizzy@pipitcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye